Shandong Xinhua Pharmaceutical Company Limited Total Assets
Shandong Xinhua Pharmaceutical Company Limited total assets. Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) holds total assets worth €9.07 Billion EUR (≈ $10.60 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shandong Xinhua Pharmaceutical Company L worth for the company's overall valuation and market capitalisation.
Total Assets of Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
Total assets of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025. This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's total assets have evolved over time, based on quarterly financial data. See Shandong Xinhua Pharmaceutical Company L share price for real-time trading data and today's change.
Shandong Xinhua Pharmaceutical Company Limited - Asset Composition Analysis
Shandong Xinhua Pharmaceutical Company Limited Total Assets Breakdown (December 2025)
Shandong Xinhua Pharmaceutical Company Limited total assets breakdown as of December 2025. Shandong Xinhua Pharmaceutical Company Limited's total assets of €9.07 Billion consist of 43.9% current assets and 56.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.2% |
| Accounts Receivable | €862.39 Million | 9.4% |
| Inventory | €1.32 Billion | 14.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €587.16 Million | 6.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shandong Xinhua Pharmaceutical Company L current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Xinhua Pharmaceutical Company Limited's current assets represent 43.9% of total assets in 2025, an increase from 38.1% in 2013.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2025, up from 10.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, unchanged from 6.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 14.4% of total assets.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Total Assets
Key competitors of Shandong Xinhua Pharmaceutical Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Shandong Xinhua Pharmaceutical Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 1.24 | 1.33 |
| Quick Ratio | 1.23 | 0.87 | 0.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.76 Billion | €764.59 Million | €701.28 Million |
Shandong Xinhua Pharmaceutical Company Limited - Advanced Valuation Insights
This section examines the relationship between Shandong Xinhua Pharmaceutical Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €9.19 Billion |
| Market Capitalization | $132.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Xinhua Pharmaceutical Company Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Xinhua Pharmaceutical Company Limited's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
The table below shows the annual total assets of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €9.19 Billion ≈ $10.74 Billion |
+1.84% |
| 2024-12-31 | €9.02 Billion ≈ $10.54 Billion |
+8.85% |
| 2023-12-31 | €8.29 Billion ≈ $9.69 Billion |
+0.25% |
| 2022-12-31 | €8.27 Billion ≈ $9.66 Billion |
+12.73% |
| 2021-12-31 | €7.33 Billion ≈ $8.57 Billion |
+3.37% |
| 2020-12-31 | €7.09 Billion ≈ $8.29 Billion |
+10.21% |
| 2019-12-31 | €6.44 Billion ≈ $7.52 Billion |
+8.79% |
| 2018-12-31 | €5.92 Billion ≈ $6.92 Billion |
+12.18% |
| 2017-12-31 | €5.27 Billion ≈ $6.17 Billion |
+11.66% |
| 2016-12-31 | €4.72 Billion ≈ $5.52 Billion |
+5.13% |
| 2015-12-31 | €4.49 Billion ≈ $5.25 Billion |
+5.82% |
| 2014-12-31 | €4.25 Billion ≈ $4.96 Billion |
+5.88% |
| 2013-12-31 | €4.01 Billion ≈ $4.69 Billion |
-- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more